Every oncology launch leaves a commercial fingerprint.

The next drug reshaping your market is already in the pipeline. Oncalix maps two decades of launch patterns so you can see it coming — and build your strategy around it — before the window closes.

The intelligence is there. Getting to it shouldn't take months.

Pipeline databases track what's in development. Claims data measure what's already happened. Between them is an 18–24 month window where pipeline events are knowable but their commercial impact isn't being modeled — and that's when commercial teams are making their most consequential decisions. Oncalix operates in that gap — translating clinical and regulatory events into structured competitive intelligence that commercial teams can act on.

What Oncalix Answers

ECHO™
Launch Analogue & Expansion

Which historical launches actually predict yours?

Identifies historical approvals with matching competitive and clinical profiles to predict your commercial trajectory, with full expansion chain analysis across indications.

FLARE™
Pipeline Threat Intelligence

Which pipeline drugs will displace your patients — and when?

Detects and monitors competitive threats, classifies them by displacement risk, and continuously alerts when regulatory events shift your competitive landscape.

SCOPE™
Patient Population Sizing

What is your real addressable population?

Narrows from total incidence through biomarker prevalence, testing rates, line-of-therapy dynamics, and competitive displacement to calculate the patients your drug can actually reach.

See Oncalix intelligence applied to your competitive context.

We'll show you what the analysis looks like for your specific indication — a threat map, a patient funnel, an analogue chain — something concrete you can evaluate against what your team already knows.

The Foundation

Three products. One interconnected registry.

Every Oncalix analysis is built on ORIS™ — our Oncology Registry for Insight & Strategy. Unlike drug-level databases, ORIS treats each FDA approval as a separate competitive entity. Pembrolizumab isn't one record — it's more than 40 distinct approval events across oncology, each with its own clinical data, competitive context, and commercial trajectory. That architectural decision changes everything.

◆
Every FDA Oncology Approval — 20 Years
Complete registry of oncology approvals across tumor types — every regimen, every indication, every competitive context, encoded into a structured system
◆
100+ Structured Fields Per Approval
Clinical, regulatory, and commercial data linked at the individual approval level. Includes proprietary launch archetype classifications that characterize each approval’s competitive and commercial profile
◆
Continuous Pipeline Surveillance
Active pipeline trials monitored from regulatory filings, clinical registries, and conference data — linked directly to the approved registry so every pipeline threat maps to the patients and products it could displace
ECHO™
Evidence-based Comparison of Historical Outcomes

Launch Analogue Matching & Expansion Chains

Identifies historical oncology approvals whose clinical data, competitive context, and market dynamics most closely match your asset — using ORIS's proprietary matching architecture. Provides launch context and addressable population benchmarks for each analogue. Also maps historical expansion chain pathways — which indications analogues expanded into after initial approval, in what sequence, and what outcomes resulted.

FLARE™
Forward-Looking Assessment of Regulatory Events

Pipeline Threat Intelligence

Maps every competitive asset in your indication setting and models the patients each one would take from you if it succeeds — not just whether it's a threat, but how many of your patients are actually at risk, and when. AI-driven surveillance monitors filings, trial registries, and evidence sources continuously, surfacing relevant changes for expert review before alerting clients.

SCOPE™
Sizing Clinical Opportunity & Patient Estimation

Patient Population Sizing

Builds the patient funnel from the ground up — real-world data across epidemiology, biomarker prevalence, testing rates, line-of-therapy dynamics, and competitive displacement — to calculate the patients your drug can actually reach. Includes sensitivity modelling showing how your addressable population changes under different testing, competitive, and guideline scenarios.

Intelligence that never goes stale.

Every Oncalix engagement includes continuous updates. Your competitive intelligence doesn’t expire when the initial project ends.

Step 1 — Structured Engagement

A tailored competitive intelligence package for your product, delivered as structured, decision-ready documents. Fixed scope, fixed price, typical turnaround 1–2 weeks.

Step 2 — Continuous Monitoring

Commercial-context alerts on relevant events, quarterly refreshes of your original analyses, and rapid-turnaround updates when material changes shift the competitive landscape. Priced as an annual subscription based on the number of assets and indications under coverage.

The initial engagement is a snapshot. The subscription keeps it current — so a competitor's breakthrough designation, a Phase 3 readout, or an NCCN guideline update reaches your team when it happens, not when it surfaces in a conversation you weren't prepared for.

Selected Examples

How oncology teams use Oncalix.

Every engagement is tailored to a specific asset and competitive context. These scenarios illustrate the types of questions Oncalix is built to answer.

Pre-Launch Strategy

Indication Expansion Strategy

The Scenario

You've just received your first FDA approval in a 2L setting. The board wants an expansion roadmap: which indications to pursue next, in what order, and what the commercial upside looks like at each step. Your team has hypotheses but no structured framework for evaluating them.

What Oncalix Delivers

ECHO maps your approval profile against historical drugs with similar first approvals — revealing the expansion chains that generated the highest cumulative commercial value.

SCOPE sizes the addressable patient population at each potential expansion step, so you can prioritize by actual patient volume, not assumed market size.

FLARE overlays pipeline competition on each expansion path — showing which directions are open and which are closing.

The Insight

Among historical analogues with your competitive profile, the most successful expansion sequence was adjuvant followed by 1L combination. But FLARE identifies two Phase 3 competitors targeting your highest-value expansion path — the window may be 3 years, not 5.

ECHOSCOPEFLARE
Illustrative
Analogue A
2L Metastatic
~4,200
→
Adjuvant
~12,000
→
1L Combo
~18,500
~35K
Total Addressable
Patients / yr
Analogue B
2L Metastatic
~4,200
→
1L Mono
~11,000
→
Head & Neck
~2,800
~18K
Total Addressable
Patients / yr
FLARE: 2 Phase 3 competitors targeting your highest-value expansion path. Window narrowing from 5 years to 3.
Insight: The most successful expansion sequence was adjuvant followed by 1L combination — capturing the largest patient stratum after establishing earlier-line evidence. But the competitive window on that path is closing.
Business Development

In-Licensing Due Diligence

The Scenario

Your BD team is evaluating an in-licensing opportunity: a Phase 3 oncology asset in a biomarker-defined subpopulation. The licensor's projections show a $500M peak revenue opportunity. Your team needs to pressure-test that number before committing $200M+ in upfront and milestone payments.

What Oncalix Delivers

SCOPE builds the real patient funnel — from incidence through biomarker prevalence, testing rates, and competitive displacement — often revealing addressable populations 30–60% below licensor estimates.

ECHO identifies historical approvals with matching clinical profiles and shows their actual commercial trajectories — what revenue analogues actually achieved, not what models predicted.

The Insight

The licensor's 12,000-patient addressable estimate becomes 4,200 after accounting for CDx testing rates and 1L competitive displacement. ECHO analogues show peak revenues of $180M–$320M for comparable launches — credible, but materially below the licensor's model.

SCOPEECHO
Illustrative
Licensor Estimate
12,000
−65%
SCOPE Analysis
4,200
Finding: The licensor's 12,000-patient addressable estimate becomes 4,200 after accounting for CDx testing rates and 1L competitive displacement — a 65% reduction.
In-Line Asset Defense

Competitive Event Response

The Scenario

A competitor just reported positive Phase 3 results at a major medical congress targeting the same 2L patient population as your launched product. Your commercial leadership wants to know — within days, not months — what this means for your franchise and what to do about it.

What Oncalix Delivers

FLARE immediately classifies the threat type, maps which patient segments are at risk of displacement, and estimates the timeline to regulatory action based on the competitor's clinical profile and designation status.

SCOPE recalculates your addressable population under the new competitive scenario — showing the before-and-after impact on your patient funnel, segment by segment.

The Insight

The competitor's data is strong in biomarker-positive patients (your 40% of franchise revenue) but weak in biomarker-negative. Displacement risk is concentrated in a single patient stratum. Recommendation: accelerate your biomarker-negative data presentation and reallocate share-of-voice to the segments where your position is defensible.

FLARESCOPE
Illustrative
Competitor X — Congress Ph3 Readout
ADC · Same 2L setting · Biomarker-positive
High Risk
Biomarker-Positive
AT RISK
~2,500 pts
40% of your franchise
Biomarker-Negative
DEFENSIBLE
~3,700 pts
60% of your franchise
Finding: Displacement risk is concentrated in one patient stratum. The biomarker-negative segment — 60% of your franchise — is defensible. Recommendation: accelerate biomarker-negative data presentation and reallocate share-of-voice.

Have a different scenario? Every engagement starts with your specific asset.

About

Domain expertise, encoded.

Oncalix was founded on a simple observation: the analytical questions driving oncology launch decisions are structurally identical across drugs and tumor types, yet every company pays to answer them from scratch. We built the system that changes that.

How We Build Intelligence

From raw data to structured insight.

Every Oncalix output follows the same rigorous pipeline — combining AI-powered data extraction with domain expert verification to produce intelligence you can trust.

01

Data Sourcing

FDA labels, NCCN guidelines, SEC filings, clinical trial registries, congress presentations — structured extraction from authoritative sources

02

AI Extraction

Large language models parse, normalize, and structure data into ORIS’s 100+ field architecture at the individual approval level

03

Expert Verification

Every extracted data point is validated by domain experts with 20 years of oncology commercial strategy experience

04

Structured Output

ECHO, FLARE, and SCOPE products generate intelligence outputs — patient funnels, threat maps, expansion chains — ready for decision-making

Our Approach

Built with AI. Verified by Experts.

ORIS is built through a rigorous process that combines AI-powered data extraction, pattern recognition, and cross-referencing with expert curation by oncology commercial strategists. Every data point is AI-surfaced and human-verified. Every analytical relationship — proprietary matching classifications, expansion chain links, threat classifications — is expert-validated before it enters the registry.

The result is intelligence you can trust at the speed only technology can deliver. AI handles the scale. Experts ensure the accuracy. You get both.

Founder
Pankaj Gupta, Founder

Pankaj Gupta

LinkedIn

Twenty years of US oncology commercial consulting — building the competitive intelligence, launch analytics, and patient flow models that pharma companies use to make their biggest commercial decisions. VP Analytics at a leading consulting firm. Director and Senior Director at IQVIA, where the work touched every major oncology launch in the US market.

After two decades of building these analyses one-off for the largest pharma companies, the pattern became clear: the analytical framework itself was the product. The questions were always the same — which pipeline drugs threaten my patients, how large is my real addressable population, and which historical launches predict mine? Different drug, different tumor type, same analytical architecture.

Oncalix is that architecture — structured, reproducible, and accessible to any oncology commercial team, regardless of size.

Follow Oncalix on LinkedIn
Let’s discuss your asset

Start a conversation.

We'll show you what the analysis looks like for your specific indication — a threat map, a patient funnel, an analogue chain — something concrete you can evaluate against what your team already knows.

Prefer email?

Request Sample Output

Fill in your details and we'll send you the full sample analysis for review.